Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
← catalyst calendarSponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Basic science
Enrollment
8actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-03 | actual | When the study began enrolling |
| Primary completion | 2026-04-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-06 | actual | The whole study's end, after follow-up |
| First posted | 2026-01-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Intervention
- Drug: Quemliclustat
Primary outcomes
what the primary-completion date above is the date OFPercentage of total radioactivity excreted in urine and feces
measured Up to 40 days
Total radioactivity in blood
measured Up to 40 days
Total radioactivity in plasma
measured Up to 40 days
Excretion of total radioactivity in urine
measured Up to 40 days
Excretion of total radioactivity in feces
measured Up to 40 days
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed